Drug Detail

Information about BIIB022

Generic Name
IND	BIIB022
Brand Name (US)
Manufacturer	Biogen Idec
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Preclinical
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

Links
Trials of this drug
	Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Trial results
	ASCO 2010 - Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.